Home » Stocks » BBI

Brickell Biotech, Inc. (BBI)

Stock Price: $1.41 USD 0.20 (16.53%)
Updated Jan 22, 2021 1:10 PM EST - Market open
Market Cap 64.75M
Revenue (ttm) 2.46M
Net Income (ttm) -24.41M
Shares Out 28.11M
EPS (ttm) -3.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $1.41
Previous Close $1.21
Change ($) 0.20
Change (%) 16.53%
Day's Open 1.21
Day's Range 1.20 - 1.45
Day's Volume 5,542,019
52-Week Range 0.48 - 3.15

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 month ago

T opline results from the U.S. pivotal Phase 3 program anticipated in the fourth quarter of 2021 Sofpironium bromide gel, 5% (ECCLOCK ® ) recently launched in Japan by development partner, Kak...

GlobeNewsWire - 2 months ago

Kaken plans to launch ECCLOCK ® for the treatment of primary axillary hyperhidrosis in Japan on November 26, 2020 - - - ECCLOCK ® placed on Japan's National Health Insurance (NHI) drug reimbur...

GlobeNewsWire - 2 months ago

BOULDER, Colo., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated...

Seeking Alpha - 2 months ago

Brickell Biotech, Inc. (BBI) CEO Robert Brown on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

Recently completed capital raise expected to fully fund U.S. pivotal Phase 3 program, with topline results anticipated in Q4 2021 - - - Initiated the Cardigan I study, the first of two U.S. pi...

GlobeNewsWire - 2 months ago

BOULDER, Colo., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated...

GlobeNewsWire - 2 months ago

BOULDER, Colo., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated...

GlobeNewsWire - 3 months ago

Primary axillary h yperhidrosis is estimated to affect over 1 0 million p eople in the U.S .

GlobeNewsWire - 3 months ago

Japan is the first country to approve sofpironium bromide with commercial launch expected later this year

GlobeNewsWire - 4 months ago

BOULDER, Colo., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentia...

GlobeNewsWire - 4 months ago

Advancement of the U.S. based program will be dependent upon results generated from AnGes’ ongoing and planned clinical studies in Japan Advancement of the U.S. based program will be dependent...

GlobeNewsWire - 4 months ago

Claims directed to novel crystalline forms of sofpironium bromide

Seeking Alpha - 5 months ago

Brickell Biotech, Inc. (BBI) CEO Robert Brown on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

Positive data from the Sofpironium Bromide Phase 3 pivotal study in Japan presented in Q2 2020 by development partner, Kaken Kaken to receive regulatory decision in Japan for sofpironium br...

GlobeNewsWire - 5 months ago

BOULDER, Colo., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiat...

GlobeNewsWire - 7 months ago

BOULDER, Colo., June 17, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiat...

GlobeNewsWire - 7 months ago

Data based on registration study in Japan of sofpironium bromide gel, 5% in patients with primary axillary hyperhidrosis

Forbes - 7 months ago

As tensions continue to rise both domestically and internationally, taking a short position isn't a bad idea. Our deep learning algorithms have identified these 5 companies as the top stocks t...

Other stocks mentioned: DGLY, EYPT, HTBX, MNKD
Seeking Alpha - 8 months ago

Brickell Biotech, Inc. (BBI) CEO Robert Brown on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 8 months ago

Announces top-line results from 12-month, Phase 3, long-term safety study Announces top-line results from 12-month, Phase 3, long-term safety study

TechCrunch - 8 months ago

SFC (formerly known as Startup Funding Club – a UK a seed stage investor – has received £10 million from British Business Investments (the commercial subsidiary of the British Business Bank), ...

Seeking Alpha - 10 months ago

Brickell Biotech, Inc. (BBI) CEO Rob Brown on Q4 2019 Results - Earnings Call Transcript

Market Watch - 11 months ago

Shares of Brickell Biotech Inc. BBI, +60.86% were vaulted 61% higher on very heavy volume, putting them on track for the biggest one-day gain since the biopharmaceutical company went public 27...

Benzinga - 11 months ago

Shares of thinly traded nano-cap biotech Brickell Biotech Inc (NASDAQ: BBI) are skyrocketing on above-average volume Thursday.

GlobeNewsWire - 11 months ago

BOULDER, Colo., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiat...

GlobeNewsWire - 11 months ago

BOULDER, Colo., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. and its subsidiary (collectively, “Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on devel...

GlobeNewsWire - 1 year ago

BOULDER, Colo., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiat...

About BBI

Brickell Biotech, a clinical-stage pharmaceutical company, focuses on identifying, developing, and commercializing various prescription therapeutics for the treatment of debilitating skin diseases in the United States. The company's lead product candidate is sofpironium bromide that is in phase 3 clinical trial to treat patients with primary axillary hyperhidrosis. Its pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions. Brickell Biotech, Inc. has a collaboration agreement with AnGes... [Read more...]

Industry
Biotechnology
Founded
2009
CEO
Robert Brown
Employees
15
Stock Exchange
NASDAQ
Ticker Symbol
BBI
Full Company Profile

Financial Performance

In 2019, BBI's revenue was $7.92 million, a decrease of -27.29% compared to the previous year's $10.89 million. Losses were -$23.88 million, 158.5% more than in 2018.

Financial Statements